Clinical Trials

370 enrolled

Lymphoma, Melanoma

NCT03598998 2026-05-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

13 enrolled 12 charts

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT03789097 2026-05-22

Vaccination With Flt3L, Radiation, and Poly-ICLC

BreastHead & NeckLymphoid

17 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT06137144 2026-05-19

PRIMAVERA

161 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Peripheral

NCT02362035 2026-05-13

KEYNOTE145

LymphoidOther hematologic neoplasmPlasma cell

161 enrolled 29 charts

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03035331 2026-05-04

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

LymphoidOther hematologic neoplasm

11 enrolled 12 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03983668 2026-03-30

CMP-001 for Relapsed and Refractory Lymphoma

14 enrolled 11 charts

Lymphoma

NCT04752826 2026-02-18

MK-3475-D20

DermatologicGynecologicLymphoid

176 enrolled

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT03598608 2026-02-05

MK-4280-003

137 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03829254 2026-01-12

A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

135 enrolled

Lymphoma, Melanoma

NCT03278782 2026-01-09

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

39 enrolled

Immunoblastic Lymphadenopathy, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT03160079 2025-11-10

Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts

16 enrolled 14 charts

Burkitt Lymphoma, Recurrence

NCT03331341 2025-08-05

Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma

50 enrolled 10 charts

Hodgkin Disease

NCT03512405 2025-05-30

Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia

LymphoidOther hematologic neoplasm

36 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03058289 2025-02-27

IT-01

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

111 enrolled 21 charts

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT03674567 2025-01-24

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination with Pembrolizumab

BreastGenitourinaryGynecologicHead & NeckLymphoidThoracic

323 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Lymphoma

NCT03153202 2024-11-19

Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)

LymphoidOther hematologic neoplasm

23 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT03309878 2023-09-21

Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

8 enrolled 10 charts

Lymphoma, Large B-Cell, Diffuse

NCT02535247 2022-07-08

Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma

17 enrolled 7 charts

Lymphoma, T-Cell, Peripheral

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

444 enrolled 19 charts

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

NCT03873025 2021-08-17

PLACARD

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02650999 2021-07-22

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

12 enrolled 8 charts

Lymphoma, Follicular, Lymphoma, Mantle-Cell

NCT03586024 2021-05-07

Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas

Phase 1/2 Withdrawn

Lymphoma

NCT02501473 2020-09-09

MK-3475-174

52 enrolled 23 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT02875067 2020-08-14

Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma

6 enrolled 5 charts

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT02408042 2017-06-27

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Phase 1/2 Withdrawn